STOCK TITAN

Eledon Pharmaceuticals, Inc. - ELDN STOCK NEWS

Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a clinical-stage biotechnology company dedicated to developing immune-modulating therapies for life-threatening conditions. The company's main focus lies in targeting the CD40L pathway, aiming to provide novel treatments for organ and cellular transplantation, autoimmune diseases, and neurodegenerative conditions.

At the core of Eledon's research is tegoprubart, a humanized IgG1 anti-CD40L antibody. Tegoprubart shows high affinity for CD40 Ligand (CD40L), a crucial biological target involved in generating pro-inflammatory responses in autoimmune diseases, transplant rejection, and neuroinflammation. The CD40/CD40L pathway is essential in both adaptive and innate immune responses, making it a prime target for non-lymphocyte depleting therapeutic interventions.

In 2023, Eledon achieved significant milestones, including presenting initial clinical evidence of tegoprubart's potential to prevent organ rejection while maintaining robust kidney function and a favorable safety profile. The company also played a pivotal role in the second-ever genetically modified heart transplant from a pig to a human, using tegoprubart as a key immunosuppressive component.

Looking forward to 2024, Eledon is committed to advancing its clinical programs. Key initiatives include ongoing development in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). The firm has several pivotal studies underway, including a Phase 1b trial for kidney transplantation, a long-term safety and efficacy extension study, and the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus in kidney transplant patients.

Financially, Eledon reported a net loss of $40.3 million for 2023, slightly improved compared to the previous year's $88.0 million, which included a significant non-cash goodwill impairment charge. The firm's research and development expenses increased to $30.3 million, underscoring its commitment to advancing its clinical pipeline.

Eledon Pharmaceuticals is headquartered in Irvine, California, and continually seeks to build on its deep historical knowledge of anti-CD40L biology to develop groundbreaking therapies. For more information, visit www.eledon.com.

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) has received a No Objection Letter from Health Canada for its clinical trial application of AT-1501, intended to replace tacrolimus in kidney transplant patients. This multicenter, open-label study will involve 6 to 12 subjects to assess AT-1501’s safety, efficacy, and pharmacokinetics. Interim data is expected in late 2022. According to CEO David-Alexandre Gros, this study aims to potentially improve transplant outcomes and decrease side effects associated with current immunosuppressive therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.43%
Tags
none
-
Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) announced the appointment of Dr. Jan Hillson to its Board of Directors. Dr. Hillson is the Senior VP of Clinical Development at Alpine Immune Sciences and brings extensive experience in immunology and rheumatology. CEO David-Alexandre Gros expressed confidence that her insights will be valuable in advancing Eledon's lead drug, AT-1501, through clinical development. AT-1501 is designed to treat autoimmune diseases, organ transplants, and ALS. The company is focused on targeting the CD40L pathway for therapeutic benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
management
-
Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical-stage biopharmaceutical company, announced a corporate presentation at the Ladenburg Thalmann Healthcare Conference on July 13 at 2:00 pm EST. The company focuses on developing treatments targeting autoimmune diseases, organ transplant requirements, and ALS. Its lead compound, AT-1501, is an anti-CD40L antibody designed to enhance efficacy and safety by inhibiting CD40L, thus regulating immune responses. A replay of the presentation will be available for 30 days post-event on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
Rhea-AI Summary

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a biopharmaceutical firm focused on autoimmune diseases and organ transplant treatments, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30pm EST. Interested participants can register here.

A replay will be available for 30 days on the company’s website. Eledon is developing AT-1501, an anti-CD40L antibody, for autoimmune diseases and transplants, aiming for improved safety and efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Summary

Eledon Pharmaceuticals reported its Q1 2021 financial results, highlighting continued enrollment in the Phase 2 trial of AT-1501 for ALS, with top line data expected in H1 2022. The company appointed four key executives, enhancing its leadership team. Q1 net loss was $8.5 million, or $0.57 per share, up from $8.2 million, or $8.52 per share, year-over-year. R&D expenses surged to $5.6 million, compared to $1.6 million in 2020. Eledon has $108.6 million in cash, ensuring operational funding into 2023. Upcoming milestones include initiating additional trials and presenting data at the American Society of Transplantation conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary

Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company, announced presentations for its lead product candidate, AT-1501, at the American Transplant Congress (ATC) from June 4-9, 2021. The presentations include Phase 1 data on AT-1501's safety, tolerability, and pharmacokinetics, alongside pre-clinical data demonstrating its effectiveness in preventing islet allograft rejection in nonhuman primates. Two additional posters will cover pharmacokinetics, toxicity, and characterization of AT-1501. More information is available on the ATC website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) plans to announce its financial results for Q1 2021 on May 13, 2021, after trading closes. The management will conduct a conference call and webcast at 4:30 PM ET to discuss these results. The company focuses on developing therapies for autoimmune diseases and ALS, with its lead compound AT-1501 targeting the CD40L pathway. This innovative approach aims to improve safety and efficacy in treatments. A recording of the event will be available on Eledon's website for one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
-
Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) announced a new development strategy for AT-1501 in renal transplantation as requested by the FDA. The agency has asked for specific non-human primate data before starting a Phase 2 trial in the U.S. Consequently, Eledon will conduct evaluations in primate models, expected to be completed by late 2022. Despite this shift, other development programs continue as planned, and no safety concerns regarding AT-1501 have been reported. The CEO emphasized the potential of AT-1501 as a treatment option for renal transplant patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.4%
Tags
none
-
Rhea-AI Summary

Eledon Pharmaceuticals has announced the appointments of David Hovland, Ph.D. as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer. Dr. Hovland brings over 20 years of R&D experience, previously serving at Urovant Sciences and Allergan, while Mr. Smith has a successful track record at Urovant and Allergan. Their expertise is expected to advance the development of AT-1501, a novel antibody targeting the CD40 ligand. The company will issue stock options as inducement grants for their roles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
management
Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2020 results, highlighting a net loss of $5.9 million for Q4 and $22.8 million for the year. The company has $114.2 million in cash as of December 31, 2020, allowing it to fund multiple Phase 2 trials of its lead asset, AT-1501. Key milestones include ongoing ALS trials and islet cell transplantation trials expected to start in Q2 2021. The acquisition of Anelixis Therapeutics in September 2020 has reshaped Eledon's focus on autoimmune diseases and transplantation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags

FAQ

What is the current stock price of Eledon Pharmaceuticals (ELDN)?

The current stock price of Eledon Pharmaceuticals (ELDN) is $4.38 as of December 13, 2024.

What is the market cap of Eledon Pharmaceuticals (ELDN)?

The market cap of Eledon Pharmaceuticals (ELDN) is approximately 261.7M.

What does Eledon Pharmaceuticals specialize in?

Eledon Pharmaceuticals specializes in developing immune-modulating therapies for organ and cellular transplantation, autoimmune diseases, and neurodegenerative conditions.

What is tegoprubart?

Tegoprubart is Eledon Pharmaceuticals' lead investigational product. It is a humanized IgG1 anti-CD40L antibody with high affinity for CD40 Ligand, showing potential in preventing organ rejection and treating autoimmune diseases.

What are the recent achievements of Eledon Pharmaceuticals?

In 2023, Eledon presented initial clinical evidence of tegoprubart's effectiveness in preventing organ rejection, participated in a landmark genetically modified heart transplant, and made significant progress in clinical trials and research.

What are Eledon Pharmaceuticals' financial highlights for 2023?

Eledon reported a net loss of $40.3 million for 2023, with research and development expenses increasing to $30.3 million, reflecting the company's investment in advancing its clinical trials.

Where is Eledon Pharmaceuticals headquartered?

Eledon Pharmaceuticals is headquartered in Irvine, California.

What clinical trials are currently underway at Eledon Pharmaceuticals?

Eledon is conducting several trials, including a Phase 1b trial for kidney transplantation, a long-term safety and efficacy extension study, and the Phase 2 BESTOW trial to compare tegoprubart with tacrolimus.

How does tegoprubart work?

Tegoprubart targets the CD40/CD40L pathway, which plays a central role in immune responses. It aims to provide immunomodulatory therapeutic intervention without depleting lymphocytes.

What is the significance of the CD40/CD40L pathway?

The CD40/CD40L pathway is crucial in both adaptive and innate immune responses, making it a prime target for treatments aimed at reducing pro-inflammatory responses in autoimmune diseases and transplant rejection.

What are the future plans for Eledon Pharmaceuticals?

Eledon plans to continue advancing its clinical trials for tegoprubart, aiming to complete enrollment in the Phase 2 BESTOW trial by the end of 2024 and to further explore its use in kidney allograft transplantation, xenotransplantation, and ALS.

How can I learn more about Eledon Pharmaceuticals?

For more information, you can visit Eledon Pharmaceuticals' official website at www.eledon.com.

Eledon Pharmaceuticals, Inc.

Nasdaq:ELDN

ELDN Rankings

ELDN Stock Data

261.66M
56.14M
0.04%
42.88%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
IRVINE